Position in ABSI
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$618,300
-$99,942 QoQ
Shares Held
206,100
+0.1% QoQ
Ownership
0.132%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ABSI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026PIER 88 INVESTMENT PARTNERS LLC holds $8,185,124 across 11 Biotechnology names. ABSI ranks #6 (7.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
8,000 | $1,597,200 | |
| 2 | DNLI |
Denali Therapeutics Inc.
|
64,800 | $1,244,160 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
19,000 | $1,227,970 | |
| 4 | KRYS |
Krystal Biotech, Inc.
|
3,500 | $904,120 | |
| 5 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
1,200 | $628,164 | |
| 6 | ABSI |
Absci Corp
This page
|
206,100 | $618,300 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
7,700 | $571,802 | |
| 8 | INSM |
INSMED Inc
|
3,200 | $523,264 |
All Filings in ABSI
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $618,300 | 206,100 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $718,242 | 205,800 | Shares | Sole | 2026-02-04 | |
| 2025-09-30 | $724,067 | 238,180 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | $507,395 | 197,430 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $762,211 | 303,670 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $553,370 | 211,210 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $519,978 | 136,120 | Shares | Sole | 2024-11-06 | |
| 2024-06-30 | $456,517 | 148,220 | Shares | Sole | 2024-08-06 | |
| 2024-03-31 | $247,477 | 43,570 | Shares | Sole | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||